The present disclosure relates to stented prosthetic heart valves having a paravalvular leakage prevention or mitigation wrap, as well as delivery devices and methods for selectively deploying the wrap.
A human heart includes four heart valves that determine the pathway of blood flow through the heart: the mitral valve, the tricuspid valve, the aortic valve, and the pulmonary valve. The mitral and tricuspid valves are atrioventricular valves, which are between the atria and the ventricles, while the aortic and pulmonary valves are semilunar valves, which are in the arteries leaving the heart. Ideally, native leaflets of a heart valve move apart from each other when the valve is in an open position, and meet or “coapt” when the valve is in a closed position. Problems that may develop with valves include stenosis in which a valve does not open properly, and/or insufficiency or regurgitation in which a valve does not close properly. Stenosis and insufficiency may occur concomitantly in the same valve. The effects of valvular dysfunction vary, with regurgitation or backflow typically having relatively severe physiological consequences to the patient.
Recently, flexible prosthetic valves supported by stent structures that can be delivered percutaneously using a catheter-based delivery system have been developed for heart and venous valve replacement. These prosthetic valves may include either self-expanding or balloon-expandable stent structures with valve leaflets attached to the interior of the stent structure. The prosthetic valve can be reduced in diameter, by crimping onto a balloon catheter or by being contained within a sheath component of a delivery catheter, and advanced through the venous or arterial vasculature. Once the prosthetic valve is positioned at the treatment site, for instance within an incompetent native valve, the stent structure may be expanded to hold the prosthetic valve firmly in place. One example of a stented prosthetic valve is disclosed in U.S. Pat. No. 5,957,949 to Leonhardt et al. entitled “Percutaneous Placement Valve Stent.” Another example of a stented prosthetic valve for a percutaneous pulmonary valve replacement procedure is described in U.S. Patent Application Publication No. 2003/0199971 A1 and U.S. Patent Application Publication No. 2003/0199963 A1, both filed by Tower et al.
Although transcatheter delivery methods have provided safer and less invasive methods for replacing a defective native heart valve, leakage between the implanted prosthetic valve and the surrounding native tissue is a recurring problem. Leakage sometimes occurs due to the fact that minimally invasive and percutaneous replacement of cardiac valves typically does not involve actual physical removal of the diseased or injured heart valve. Rather, the replacement prosthetic valve is delivered in a compressed condition to the valve site, where it is expanded to its operational state within the native valve. Calcified or diseased native leaflets are pressed to the side walls of the native valve by the radial force of the stent frame of the prosthetic valve. These calcified leaflets can lead to incomplete conformance of the stent frame with the native valve and can be a source of paravalvular leakage (“PVL”). Significant pressure gradients across the valve cause blood to leak through the gaps between the implanted prosthetic valve and the calcified anatomy. When present, such paravalvular leakage is highly detrimental to the patient.
The present disclosure addresses problems and limitations associated with the related art.
As discussed above, stented prosthetic heart valves can leave paravalvular leakage pathways in some patients, particularly patients with very immobile or heavily calcified native valve leaflets. Disclosed embodiments include stented prosthetic heart valves having a stent frame with a wrap that can be optionally deployed, if paravalvular leakage is detected, to fill commissural paravalvular leakage pathways. In other words, the arrangement of the wrap is controlled independently of the configuration (i.e. expansion) of the stent frame. The wrap includes a body of flexible material positioned around an end of the stent frame. In disclosed embodiments, the wrap is configured so that in a deployed position, the wrap bulges outwardly from the stent frame as one end of the wrap is positioned closer to a second, opposing end of the wrap.
Actuation of the wrap can be accomplished in a variety of ways. For example, the delivery device can include a plurality of tethers that are connected to both a movable end of the wrap and a shaft assembly of the delivery device. The shaft assembly is configured to selectively position the tethers and, thus the wrap. Once the wrap is in the deployed position, coupling elements can be utilized to maintain the deployed position of the wrap. Exemplary coupling elements include a ratchet, hooks and barbs. In other embodiments, the wrap is constructed to be biased in the deployed position and will generally remain in the deployed position once forces overcoming the natural bias to maintain the wrap in the delivery position are released.
After the wrap is maintained in the deployed position and the stented prosthetic heart valve hemodynamics and paravalvular leakage are assessed and deemed acceptable, the delivery device is disengaged from the wrap and the stented prosthetic heart valve so that the delivery device can be retracted from the patient.
wherein the stent frame is in the expanded arrangement and the wrap is in the delivery position.
Specific embodiments of the present disclosure are now described with reference to the figures, wherein like reference numbers indicate identical or functionally similar elements. The terms “distal” and “proximal” are used in the following description with respect to a position or direction relative to the treating clinician. “Distal” or “distally” are a position distant from or in a direction away from the clinician. “Proximal” and “proximally” are a position near or in a direction toward the clinician.
Certain aspects of the present disclosure relate to transcatheter stented prosthetic heart valve delivery devices that retain a stented prosthetic heart valve (hereinafter “prosthetic valve”) in a compressed arrangement during delivery to a target site and allow the prosthetic valve to expand and deploy at a target site. By way of background, general components of one non-limiting example of a delivery device 10 with which the aspects of the present disclosure are useful is illustrated in
One or more elongate tension members 20 can optionally be provided to constrain and compress the prosthetic valve 40. Suitable elongate tension members, include, but are not limited to sutures, chords, wires or filaments. The tension member(s) 20 can be considered part of the delivery device 10 in some embodiments or as part of the prosthetic valve 40 in other embodiments. The delivery device 10 provides a loaded delivery state (
The disclosed prosthetic valve 40, which may be of many configurations as discussed herein, includes a paravalvular leakage prevention and/or mitigation wrap 60 (schematically illustrated and shown apart from the prosthetic valve in
The prosthetic valve 40 is configured so that the wrap 60 can be selectively deployed independent of the arrangement of the stent frame 42. For example,
The delivery device 10 and prosthetic valve 40 configurations disclosed herein are beneficial in that the diameter D1 of the wrap 60 can be selectively enlarged in situ. In this way, the clinician has the option of whether or not to deploy the wrap 60 based on the occurrence or lack of paravalvular leakage after the prosthetic valve 40 is deployed at a native heart valve V. For example, see
Actuating selective movement of the wrap 60 from the delivery position of
An alternate configuration and method of selectively actuating the wrap 60 is shown in
Once the wrap 60 is maintained in the deployed position via any of the various methods disclosed herein and the prosthetic valve 40 hemodynamics and paravalvular leakage are assessed and deemed acceptable, the delivery device 10 is disengaged from the wrap 60 and the prosthetic valve 40 so that the delivery device 10 can be retracted from the patient. In one embodiment, illustrated in
A similar alternate tether 226 that can be incorporated into a delivery device (e.g., the delivery device 10 of
As generally depicted in
Similar to that described with respect to
To maintain the wrap 60 of any of the disclosed embodiments in the deployed position, the stent frame 42 and/or the wrap 60 can include one or more coupling elements 70 such as a ratchet system or the like. As is generally illustrated in
In further alternate embodiments, the prosthetic valve 40 includes an alternate wrap 160 that self-transitions from a delivery position (
In alternate embodiments, largely similar to that of
As referred to herein, stented prosthetic heart valves or prosthetic valves 40 that can be modified to incorporate wraps (e.g., wraps 60, 160) disclosed above and delivered and deployed with devices and methods of the present disclosure may assume a wide variety of different configurations. For example, the prosthetic heart valves can be a biostented prosthetic heart valve having tissue leaflets or a synthetic heart valve having polymeric, metallic, or tissue-engineered leaflets, and can be specifically configured for replacing any heart valve. Thus, the prosthetic valves 40 can be generally used for replacement of a native aortic, mitral, pulmonic, or tricuspid valve, for use as a venous valve, or to replace a failed bioprosthesis, such as in the area of an aortic valve or mitral valve, for example.
In general terms, the stents or stent frames 42 of the present disclosure are generally tubular support structures having an internal area in which valve structure 48 leaflets 50 will be secured. The leaflets 50 can be formed from a variety of materials, such as autologous tissue, homologous material, xenograph material, or synthetics as are known in the art. The leaflets may be provided as a homogenous, biological valve structure, such as porcine, bovine, or equine valves. Alternatively, the leaflets 50 can be provided independent of one another (e.g., bovine, porcine or equine pericardial leaflets) and subsequently assembled to the support structure of the stent frame. In another alternative, the stent frame and leaflets can be fabricated at the same time, such as may be accomplished using high-strength nano-manufactured NiTi films produced at Advance BioProsthetic Surfaces (ABPS), for example. The stent frame support structures are generally configured to accommodate at least two (typically three) leaflets; however, replacement prosthetic valves of the types described herein can incorporate more or less than three leaflets.
Some embodiments of the stent frame 42 can be a series of wires or wire segments arranged such that they are capable of self-transitioning from a compressed or collapsed arrangement to the normal, radially expanded arrangement. In some constructions, a number of individual wires comprising the stent frame support structure can be formed of a metal or other material. These wires are arranged in such a way that the stent frame support structure allows for folding or compressing or crimping to the compressed arrangement in which the internal diameter is smaller than the internal diameter when in the normal, expanded arrangement. In the compressed arrangement, such a stent frame support structure with attached leaflets can be mounted onto a delivery device, (e.g., the delivery device 10). The stent frame support structures are configured so that they can be changed to their normal, expanded arrangement when desired, such as by the relative movement of one or more sheaths relative to a length of the stent frame.
The wires of the stent frame support structures in embodiments of the present disclosure can be formed from a shape memory material such as a nickel titanium alloy (e.g., Nitinol™). With this material, the support structure is self-expandable from the compressed arrangement to the normal, expanded arrangement, such as by the application of heat, energy, and the like, or by the removal of external forces (e.g., compressive forces). This stent frame support structure can also be compressed and re-expanded multiple times without damaging the structure of the stent frame. In addition, the stent frame support structure of such an embodiment may be laser-cut from a single piece of material or may be assembled from a number of different components.
The prosthetic valve 40 is configured for replacing an aortic valve. Alternatively, other shapes are also envisioned, adapted for the specific anatomy of the valve to be replaced (e.g., prosthetic valves in accordance with the present disclosure can alternatively be shaped and/or sized for replacing a native mitral, pulmonic, or tricuspid valve). Regardless, the valve structure 48 can be arranged to extend less than an entire length of the stent frame 42. In particular, the valve structure 48 can be assembled to, and extend along, the first end 44 of the prosthetic valve 40, whereas the second end 46 can be free of the valve structure 48 material. A wide variety of other constructions are also acceptable and within the scope of the present disclosure. For example, the valve structure 48 can be sized and shaped to extend along an entirety, or a near entirety, of a length of the stent frame 42.
Although the present disclosure has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes can be made in form and detail without departing from the spirit and scope of the present disclosure.
This application is a Divisional application of Ser. No. 15/458,387, filed on Mar. 14, 2017, entitled, “STENTED PROSTHETIC HEART VALVE HAVING A WRAP AND DELIVERY DEVICES,” now allowed, which claims the benefit of the filing date of U.S. Provisional Patent Application Ser. No. 62/307,665, filed Mar. 14, 2016, entitled “STENTED PROSTHETIC HEART VALVE HAVING A WRAP AND DELIVERY DEVICES,” the entire teachings of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
5035706 | Giantureo et al. | Jul 1991 | A |
5335398 | Schottker et al. | Aug 1994 | A |
5571175 | Vanney et al. | Nov 1996 | A |
5693084 | Chuter | Dec 1997 | A |
5776186 | Uflacker | Jul 1998 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
6280465 | Cryer | Aug 2001 | B1 |
6517550 | Konya et al. | Feb 2003 | B1 |
6733521 | Chobotov et al. | May 2004 | B2 |
6740111 | Lauterjung | May 2004 | B1 |
7033390 | Johnson et al. | Apr 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7276078 | Spenser et al. | Oct 2007 | B2 |
7329275 | Yee | Feb 2008 | B2 |
7329279 | Haug et al. | Feb 2008 | B2 |
7331991 | Kheradvar et al. | Feb 2008 | B2 |
7445631 | Salahieh et al. | Nov 2008 | B2 |
7503929 | Johnson et al. | Mar 2009 | B2 |
7524331 | Birdsall | Apr 2009 | B2 |
7534261 | Friedman | May 2009 | B2 |
7628805 | Spenser et al. | Dec 2009 | B2 |
7708775 | Rowe et al. | May 2010 | B2 |
7780725 | Haug et al. | Aug 2010 | B2 |
7972378 | Tabor et al. | Jul 2011 | B2 |
8002825 | Letac et al. | Aug 2011 | B2 |
8142497 | Friedman | Mar 2012 | B2 |
8182528 | Salahieh et al. | May 2012 | B2 |
8231670 | Salahieh et al. | Jul 2012 | B2 |
8246678 | Salahieh et al. | Aug 2012 | B2 |
8252052 | Salahieh et al. | Aug 2012 | B2 |
8403981 | Forster et al. | Mar 2013 | B2 |
8449599 | Chau et al. | May 2013 | B2 |
8603160 | Salahieh et al. | Dec 2013 | B2 |
8623078 | Salahieh et al. | Jan 2014 | B2 |
8628566 | Eberhardt et al. | Jan 2014 | B2 |
8641757 | Pintor et al. | Feb 2014 | B2 |
8668733 | Salahieh et al. | Mar 2014 | B2 |
8673000 | Tabor et al. | Mar 2014 | B2 |
8734484 | Ahlberg et al. | May 2014 | B2 |
8795357 | Yohanan et al. | Aug 2014 | B2 |
8801706 | Rothstein et al. | Aug 2014 | B2 |
8801776 | House et al. | Aug 2014 | B2 |
8808356 | Braido et al. | Aug 2014 | B2 |
8840662 | Salahieh et al. | Sep 2014 | B2 |
8840663 | Salahieh et al. | Sep 2014 | B2 |
8852272 | Gross et al. | Oct 2014 | B2 |
8926690 | Kovalsky | Jan 2015 | B2 |
8986371 | Quill et al. | Mar 2015 | B2 |
8986375 | Garde et al. | Mar 2015 | B2 |
8992608 | Haug et al. | Mar 2015 | B2 |
9011521 | Haug et al. | Apr 2015 | B2 |
9675451 | Garde et al. | Jun 2017 | B2 |
9974649 | Racchini et al. | May 2018 | B2 |
10179045 | Racchini et al. | Jan 2019 | B2 |
10888420 | Bateman et al. | Jan 2021 | B2 |
20030199963 | Tower et al. | Oct 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20040030381 | Shu | Feb 2004 | A1 |
20040111111 | Lin | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20050119722 | Styrc et al. | Jun 2005 | A1 |
20050137690 | Salahieh | Jun 2005 | A1 |
20050137695 | Salahieh et al. | Jun 2005 | A1 |
20060004442 | Spenser et al. | Jan 2006 | A1 |
20070016285 | Lane et al. | Jan 2007 | A1 |
20070244544 | Birdsall et al. | Oct 2007 | A1 |
20070270944 | Bergheim et al. | Nov 2007 | A1 |
20070293944 | Spenser et al. | Dec 2007 | A1 |
20080243245 | Thambar et al. | Oct 2008 | A1 |
20080275540 | Wen | Nov 2008 | A1 |
20090099653 | Suri et al. | Apr 2009 | A1 |
20090112311 | Miles et al. | Apr 2009 | A1 |
20090192591 | Ryan et al. | Jul 2009 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100168844 | Toomes et al. | Jul 2010 | A1 |
20100198238 | Sorajja | Aug 2010 | A1 |
20100280589 | Styrc | Nov 2010 | A1 |
20100286768 | Alkhatib | Nov 2010 | A1 |
20110040366 | Goetz et al. | Feb 2011 | A1 |
20110054466 | Rothstein et al. | Mar 2011 | A1 |
20110098802 | Braido et al. | Apr 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110172765 | Nguyen et al. | Jul 2011 | A1 |
20110245911 | Quill et al. | Oct 2011 | A1 |
20110257721 | Tabor | Oct 2011 | A1 |
20110264206 | Tabor | Oct 2011 | A1 |
20120022633 | Olson et al. | Jan 2012 | A1 |
20120041549 | Salahieh et al. | Feb 2012 | A1 |
20120041550 | Salahieh et al. | Feb 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120277734 | Goetz et al. | Nov 2012 | A1 |
20130030519 | Tran et al. | Jan 2013 | A1 |
20130190857 | Mitra et al. | Jul 2013 | A1 |
20130190862 | Pintor et al. | Jul 2013 | A1 |
20130197622 | Mitra et al. | Aug 2013 | A1 |
20130245752 | Goetz et al. | Sep 2013 | A1 |
20130245753 | Alkhatib | Sep 2013 | A1 |
20130274873 | Delaloye et al. | Oct 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20130338755 | Goetz et al. | Dec 2013 | A1 |
20130338765 | Braido et al. | Dec 2013 | A1 |
20140046426 | Kovalsky | Feb 2014 | A1 |
20140094904 | Salahieh et al. | Apr 2014 | A1 |
20140107772 | Li et al. | Apr 2014 | A1 |
20140114402 | Ahlberg et al. | Apr 2014 | A1 |
20140114406 | Salahieh et al. | Apr 2014 | A1 |
20140194975 | Quill et al. | Jul 2014 | A1 |
20140194981 | Menk et al. | Jul 2014 | A1 |
20140222144 | Eberhardt et al. | Aug 2014 | A1 |
20140236287 | Clague et al. | Aug 2014 | A1 |
20140243966 | Garde et al. | Aug 2014 | A1 |
20140243969 | Venkatasubramanian et al. | Aug 2014 | A1 |
20140257475 | Gross et al. | Sep 2014 | A1 |
20140277388 | Skemp | Sep 2014 | A1 |
20140277413 | Richter et al. | Sep 2014 | A1 |
20140277417 | Schraut et al. | Sep 2014 | A1 |
20140277419 | Garde et al. | Sep 2014 | A1 |
20140277422 | Ratz et al. | Sep 2014 | A1 |
20140277423 | Alkhatib et al. | Sep 2014 | A1 |
20140277424 | Oslund | Sep 2014 | A1 |
20140277425 | Dakin | Sep 2014 | A1 |
20140277426 | Dakin et al. | Sep 2014 | A1 |
20140277428 | Skemp et al. | Sep 2014 | A1 |
20140296975 | Tegels et al. | Oct 2014 | A1 |
20140316516 | Vidlund et al. | Oct 2014 | A1 |
20140330368 | Gloss et al. | Nov 2014 | A1 |
20140343671 | Yohanan et al. | Nov 2014 | A1 |
20140350663 | Braido et al. | Nov 2014 | A1 |
20140350665 | Braido et al. | Nov 2014 | A1 |
20140350667 | Braido et al. | Nov 2014 | A1 |
20140350668 | Delaloye et al. | Nov 2014 | A1 |
20140371844 | Dale et al. | Dec 2014 | A1 |
20150005863 | Para | Jan 2015 | A1 |
20150073540 | Salahieh et al. | Mar 2015 | A1 |
20150073541 | Salahieh et al. | Mar 2015 | A1 |
20150073544 | Gormann, III et al. | Mar 2015 | A1 |
20150073548 | Mattheny | Mar 2015 | A1 |
20150112430 | Creaven et al. | Apr 2015 | A1 |
20150122687 | Zeng et al. | May 2015 | A1 |
20150127098 | Braido et al. | May 2015 | A1 |
20150142100 | Morriss et al. | May 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150142104 | Braido | May 2015 | A1 |
20150148898 | Krivoruchko et al. | May 2015 | A1 |
20150157455 | Hoang et al. | Jun 2015 | A1 |
20150209136 | Braido et al. | Jul 2015 | A1 |
20150216654 | Braido et al. | Aug 2015 | A1 |
20150216663 | Braido et al. | Aug 2015 | A1 |
20150238315 | Rabito et al. | Aug 2015 | A1 |
20150245909 | Salahieh et al. | Sep 2015 | A1 |
20150327995 | Morin et al. | Nov 2015 | A1 |
20150327996 | Fahim et al. | Nov 2015 | A1 |
Number | Date | Country |
---|---|---|
103705315 | Apr 2014 | CN |
0537487 | Apr 1993 | EP |
1758523 | Jan 2006 | EP |
2674130 | Mar 2016 | EP |
WO2009094501 | Jul 2009 | WO |
WO2011051043 | May 2011 | WO |
WO2013033791 | Mar 2013 | WO |
WO2013059747 | Apr 2013 | WO |
WO2014072439 | May 2014 | WO |
WO2015152980 | Oct 2015 | WO |
Entry |
---|
The International Search Report and Written Opinion for International Application No. PCT/US2014/014090 mailed Apr. 14, 2014 (11 pages). |
PCT/US2017/022285, The International Search Report and the Written Opinion of the International Searching Authority, mailed Apr. 26, 2017. |
Number | Date | Country | |
---|---|---|---|
20210085455 A1 | Mar 2021 | US |
Number | Date | Country | |
---|---|---|---|
62307665 | Mar 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15458387 | Mar 2017 | US |
Child | 17116431 | US |